Inhibitory effect of arsenic trioxide on angiogenesis and expression of vascular endothelial growth factor in gastric cancer

Table 1 Tumor growth inhibition (TGI) of tumors treated with arsenic (n = 10, mean ± SD)

Group	Tumor volume (V) mm3			Mass(mg)	TGI (%)
	D 0	D6	D11		D6	D11
Control	67 ± 45	343 ± 160	999 ± 338	784 ± 185
2.5 mg/kg	63 ± 36	307 ± 80	696 ± 125a	556 ± 211a	11.7%	30.3% (29.1%)
5 mg/kg	66 ± 48	240 ± 203	491 ± 116ac	375 ± 167ac	30.0%	50.9% (52.2%)

^aP < 0.05 vs control;

^cP < 0.05 vs 2.5 mg/kg; TGI calculated using tumor volume was given in parenthesis.

Table 2 Effect of As₂O₃ on microvessel density and VEGF expression in tumor xenografts (n = 10, mean ± SD)

Group	MVD	VEGF
Control	9.32 ± 0.33	49.23 ± 2.12
2.5 mg/kg	5.36 ± 0.32b	20.07 ± 1.19b
5 mg/kg	3.05 ± 0.24bd	11.93 ± 1.07bd
F	111.841	163.461
P	< 0.001	< 0.001

^bP < 0.01 vs Control;

^dP < 0.01: vs 2.5 mg/kg.

Table 3 Effect of As₂O₃ on VEGF mRNA in SGC-7901 cell by real time RT-PCR

As2O3(μmol/L)	VEGF mRNA	β-actin mRNA	VEGF mRNA/β-actin mRNA
0	1.28 × 106	3.72 × 107	3.44 × 10-2
0.5	2.34 × 104	7.92 × 105	2.95 × 10-2
1.0	4.74 × 102	9.96 × 103	4.76 × 10-2
2.0	2.16 × 106	7.24 × 107	2.89 × 10-2
3.0	3.21 × 103	8.2 × 104	3.91 × 10-2